PFO
ELOS

Pathstone Family Office’s Syneron Medical Ltd ELOS Stock Holding History

Pathstone Family Office’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,000
Closed -$34K – 359
2013
Q3 		$34K Hold
4,000
– – 0.15% 100
2013
Q2 		$35K Buy
+4,000
New +$35.8K 0.04% 149

Other funds holding ELOS

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
HC
Hourglass Capital Houston, Texas $480M AUM 32.35% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pathstone Family Office's ELOS Position: Q4 2013 in Review

Pathstone Family Office sold out of Syneron Medical Ltd (ELOS) in Q4 2013, closing a stake of 4,000 shares — an estimated $34K sold.

Pathstone Family Office first reported a position in ELOS in Q2 2013 and held it in 2 quarters. The position peaked at $35K in Q2 2013. 67 funds tracked by Wall St. Rank hold ELOS as of Q4 2013.

  • Pathstone Family Office reported no remaining Syneron Medical Ltd position as of Q4 2013 after selling out during the quarter.
  • Pathstone Family Office sold 4,000 Syneron Medical Ltd shares in Q4 2013, an estimated $34K.
  • Pathstone Family Office first reported a position in Syneron Medical Ltd in Q2 2013 and held it in 2 quarters.
  • Pathstone Family Office's Syneron Medical Ltd position peaked at $35K in Q2 2013.
  • 67 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q4 2013.

Based on Pathstone Family Office's 13F filing for Q4 2013, filed 4 Feb 2014.